Details

The endocannabinoid system (ECS) is a group of endogenous cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems, consisting of neuromodulatory lipids and their receptors. Known as “the body’s own cannabinoid system, the ECS is involved in a variety of physiological processes including appetite, pain-sensation, mood, and memory, and in mediating the psychoactive effects of cannabis.

Two primary endocannabinoid receptors have been identified: CB1, first cloned in 1990; CB2, cloned in 1993. CB1 receptors are found predominantly in the brain and nervous system, as well as in peripheral organs and tissues, and are the main molecular target of the endocannabinoid ligand (binding molecule), Anandamide, as well as its mimetic phytocannabinoid, THC. One other main endocannabinoid is 2-Arachidonoylglycerol (2-AG) which is active at both cannabinoid receptors, along with its own mimetic phytocannabinoid, CBD. 2-AG and CBD are involved in the regulation of appetite, immune system functions and pain management

Dr. Robert Melamede, a biology professor at the University of Colorado at Colorado Springs, is president and CEO of Cannabis Science, “an emerging pharmaceutical cannabis company.” The startup, which is looking to establish its offices in the Springs, has about 10 employees, including a lab director. The company’s goal: to tap into the growing use of medical marijuana in Colorado

Julie Holland, MD (born December 13, 1965) is an American psychopharmacologist, psychiatrist, and author. She is the author of Moody Bitches: The Truth About the Drugs You’re Taking, the Sleep You’re Missing, the Sex You’re Not Having, and What’s Really Making You Crazy and Weekends at Bellevue: Nine Years on the Night Shift at the Psych ER, a memoir documenting her experience as the weekend head of the psychiatric emergency room at Bellevue Hospital in New York City